Reverie Labs
Machine learning-driven pharma company
- 21-100 employees
- Healthcare
- B2B
- Artificial Intelligence
- Biology
- Machine Learning
- MedTech
- Central Square, Cambridge, MA
Jump to section
Company mission
Reverie Labs is on a mission to develop next-generation cancer therapies.
Our take
Reverie is attempting to disrupt, or rather supplement, the pharmaceuticals industry by using AI and Machine Learning, as well as a team of engineers and chemists, to develop new medicines.
AI’s use in drug discovery has been growing for the last decade as biotech companies steadily adopt the technology, but Reverie Labs’ status as an AI-first pharma company could well give it an advantage. Indeed, the startup has made a huge breakthrough with its discovery of brain penetrant kinase inhibitors, a type of enzyme blocker which can be used to treat cancer.
This has led to partnerships with legacy pharma company Roche and its subsidiary Genentech, as well as major venture capital backing from Ridgeback Capital Investments, which it’s using to develop its drug discovery platform and expand its headcount.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Flexible paid time off & extended leave
- Generous equity grants
- 401(k) with matching
- Blue Cross Blue Shield Insurance
- Premium gym membership subsidy at VIM Fitness
- Tax-advantaged commuter benefits
- Company events
- One Medical membership
- Home office reimbursement
Funding (2 rounds)
Feb 2021
$25m
SERIES A
Jan 2018
$0.2m
SEED
Total funding: $25.2m
This company has top investors
Leadership
Jonah Kallenbach
(CEO)Former Research Assistant at Fox Chase Cancer Center, and Harvard's Centers for Biomedical Informatics and Systems Software.
Ankit Gupta
(CTO)Former Research Engineer at Vicarious AI, and former Machine Learning Researcher at The Harvard John A. Paulson School of Engineering and Applied Sciences.